Remove Antibody Remove Development Remove Genotoxicity Remove Protein
article thumbnail

IN FOCUS: Solvias

Pharmaceutical Technology

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Trodelvy is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. months vs. 6.9 months (HR: 0.51; 95% CI: 0.41-0.62;

HR 52
article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. About Trodelvy.